The VEGF inhibitor bevacizumab improves chemotherapy outcomes for some patients [8] and, although other anti-angiogenic therapies have not been successful in trials, there remains an interest in targeting abnormal tumour vasculature in MPM [55]. Here, VEGFA is linked to neoplasm.